Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boothman-Burrell, D.
Right arrow Articles by Taylor, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boothman-Burrell, D.
Right arrow Articles by Taylor, D. R.
(Chest. 1997;112:12-18.)
© 1997 American College of Chest Physicians

The Effect of Regular Salbutamol on Lung Function and Bronchial Hyperresponsiveness in Normal Subjects and Nonasthmatic Atopic Subjects With Allergic Rhinitis

David Boothman-Burrell MBChB1; David Jones BSc1; G. Peter Herbison BSc1; and D. Robin Taylor MD1

1 From the Departments of Respiratory Medicine and Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand

Background: The effects of regular inhaled β-agonist treatment on lung function remain a controversial issue. In an earlier study, the administration of regular inhaled salbutamol resulted in negative changes in FEV1 not only in asthmatics, but also in nonasthmatic atopic subjects.

Objective: The aim of this study was to confirm these findings and also to examine whether regular inhaled salbutamol would increase bronchial hyperresponsiveness in atopic or normal individuals.

Design: The study was a randomized, double-blind, placebo-controlled, crossover investigation.

Participants: There were two groups: 10 normal healthy subjects (group A) and nine nonasthmatic atopic subjects (group B).

Interventions: Subjects received inhaled salbutamol or identical placebo for periods of 6 weeks, the dose being increased in stepwise fashion at 2-week intervals.

Measurements: Changes in lung function were assessed by measuring spirometric values, airways conductance, and changes in complete and partial expiratory flow volume curves. Changes in these parameters following a methacholine challenge were used to assess bronchial hyperresponsiveness.

Results: No statistically significant differences in lung function or bronchial hyperresponsiveness were noted to occur as the result of treatment in either group.

Conclusion: Our results do not support the view that regular inhaled salbutamol in normal or atopic subjects without asthma causes adverse changes in the airways.

Key Words: adverse effects • atopy • beta-agonist • bronchial hyperresponsiveness • rhinitis • salbutamol

Submitted on September 9, 1996
Accepted on January 23, 1997




This article has been cited by other articles:


Home page
 ChestHome page
Y. Y. Koh, Y. Park, J. H. Jeong, C. K. Kim, Y.-G. Min, and J. G. Chi
The Effect of Regular Salbutamol on Lung Function and Bronchial Responsiveness in Patients with Primary Ciliary Dyskinesia
Chest, February 1, 2000; 117(2): 427 - 433.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Chest Physicians.